Candel Therapeutics (CADL) Assets Average (2021 - 2025)

Candel Therapeutics (CADL) has 5 years of Assets Average data on file, last reported at $109.4 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average rose 70.42% year-over-year to $109.4 million; the trailing twelve-month figure through Dec 2025 stood at $109.4 million (up 70.42% YoY), and the FY2025 full-year result was $116.0 million, up 56.73% from the prior year.
• Assets Average rose to $109.4 million in Q4 2025, from $99.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $109.4 million in Q4 2025 to a low of $24.0 million in Q3 2024.
• A 5-year average of $73.3 million and a median of $76.9 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average plunged 55.87% in 2024 and jumped 315.75% in 2025, its largest moves.
• Tracing CADL's Assets Average over 5 years: stood at $92.6 million in 2021, then slipped by 12.13% to $81.3 million in 2022, then slumped by 43.91% to $45.6 million in 2023, then soared by 40.68% to $64.2 million in 2024, then surged by 70.42% to $109.4 million in 2025.
• Business Quant data shows CADL's Assets Average at $109.4 million in Q4 2025, $99.8 million in Q3 2025, and $100.9 million in Q2 2025.